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Abstract
Background: Rapid and cost-effective methods for HIV-1 diagnosis and viral load monitoring would greatly enhance the
clinical management of HIV-1 infected adults and children in limited-resource settings. Recent recommendations to treat
perinatally infected infants within the first year of life are feasible only if early diagnosis is routinely available. Dried blood
spots (DBS) on filter paper are an easy and convenient way to collect and transport blood samples. A rapid and cost
effective method to diagnose and quantify HIV-1 from DBS is urgently needed to facilitate early diagnosis of HIV-1 infection
and monitoring of antiretroviral therapy.
Methods and Findings: We have developed a real-time LightCycler (rtLC) PCR assay to detect and quantify HIV-1 from DBS.
HIV-1 RNA extracted from DBS was amplified in a one-step, single-tube system using primers specific for long-terminal
repeat sequences that are conserved across all HIV-1 clades. SYBR Green dye was used to quantify PCR amplicons and HIV-1
RNA copy numbers were determined from a standard curve generated using serially diluted known copies of HIV-1 RNA.
This assay detected samples across clades, has a dynamic range of 5 log10, and %CV ,8% up to 4 log10 dilution. Plasma HIV-
1 RNA copy numbers obtained using this method correlated well with the Roche Ultrasensitive (r=0.91) and branched DNA
(r=0.89) assays. The lower limit of detection (95%) was estimated to be 136 copies. The rtLC DBS assay was 2.5 fold rapid as
well as 40-fold cheaper when compared to commercial assays. Adaptation of the assay into other real-time systems
demonstrated similar performance.
Conclusions: The accuracy, reliability, genotype inclusivity and affordability, along with the small volumes of blood required
for the assay suggest that the rtLC DBS assay will be useful for early diagnosis and monitoring of pediatric HIV-1 infection in
resource-limited settings.
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Introduction
It is estimated that 33.2 million people were infected with HIV-
1 at the end of 2007; 2.5 million were children under 15 years of
age, the majority of whom acquired infection through mother-to-
child transmission (MTCT; [1]). Antiretroviral therapy (ART) is
effective at blocking MTCT and can markedly improve the
outcome of pediatric HIV-1 infection. However, efforts to provide
widespread access to ART have been hampered by the limited
availability of infant diagnostic methods.[2–6] Methods to
diagnose and monitor HIV-1 infection in resource-poor settings
are usually limited to serologic assays and CD4/CD8
counts.[2,7,8] However, antibody based assays can reliably guide
diagnosis and management only after 18 months of age following
clearance of passively transferred maternal antibodies.[9] PCR
based nucleic acid amplification and quantification of HIV-1 is the
gold standard for early HIV-1 diagnosis in infants and for
evaluating ART efficacy.[2,5,10–16] Several commercial nucleic
acid based molecular tests are available for HIV-1 diagnosis and
viral load quantification.[15] These commercial assays require
relatively large volumes of blood that need to be processed for
plasma, stored, and transported under special conditions. The
cost, run-time, training, maintenance and infrastructure needed to
perform these assays have also limited their use in low resource
settings.[6,17,18] Practical and reliable methods to obtain, store,
and transport blood samples are necessary to develop cost effective
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5819early diagnostic assays in limited-resource settings. Spotting of
whole blood onto filter paper offers technical and economic
advantages over conventional venipuncture methods since it
simplifies sample collection and transport to reference laboratories
for diagnostic testing and viral load quantification.[17,19–24]
In the present study, we describe a LightCycler-based real time
PCR assay (rtLC) to quantify viral loads using RNA extracted from
filter paper containing dried blood spots. DBS prepared either
under controlled conditions in a laboratory setting by research
technicians or in a clinical setting by health-professionals were
successfully evaluated. This assay has comparable reproducibility,
diagnostic accuracy, specificity and broader linear range at a lower
cost compared to probe-based commercial assays. The rtLC HIV-1
DBS assay is also capable of detecting and quantifying different
clades of HIV-1 without sacrificing sensitivity.
Methods
Patients and Reference Samples
Study Participants. In this prospective study, blood samples
were drawn by trained healthcare professionals from 33 HIV-1
positive children who presented to the UMass Mother-Child HIV
Program clinic for routine care between May 2005 and September
2008. Study participants ranged in age from 5 to 21 years. Four
HIV-1 positive adults who were enrolled in a study of viral kinetics
between 1999 and 2002 were also included in the study. Thirty
patients were of U.S. origin and were infected with clade B HIV-1,
while 7 were of non-U.S. origin, infected with non-B. Nineteen
(51%) of the 37 HIV-1 patients were on ART and eight (22%) had
undetectable RNA by Versant HIV-1 RNA 3.0 branched DNA
(bDNA) assay (Siemens Healthcare Diagnostics) or Ultrasensitive
Amplicor HIV-1 Monitor v1.5 assay (Roche Diagnostics) (Table 1).
These tests were performed by trained technicians. Blood samples
were also drawn from 44 HIV-1 negative individuals (27 adults, 17
children). Individual patient consent was obtained from study
participants and guardians and no adverse events were associated
with drawing of blood for the study. The Human Subjects
Committee of the University of Massachusetts Medical School
approved all studies.
In addition, DBS samples were collected between February
2008 and January 2009 by heel-stick from 19 infants born to HIV-
1 positive mothers at the HEAL Africa Hospital (Goma,
Democratic Republic of Congo). Informed consent for testing
was obtained from the infants’ guardians. These studies were
exempt under the guidelines of the Human Subjects Committee of
the University of Massachusetts Medical School since the samples
were received in the lab as coded, de-identified DBS with no
traceable patient information.
Preparation of DBS. At the UMass clinic, whole blood was
drawn by venipuncture and collected in tubes with EDTA. DBS
were prepared by spotting 50 ml of whole blood onto filter paper
(Whatman no. 903; formerly SS 903, Schleicher & Schuell, Keene,
NH). For 6 of the 23 patients, cryopreserved plasma was spiked
into donor HIV-1 negative blood to prepare DBS since whole
blood was not available. The spotted filter papers were allowed to
dry for at least 4 hours at room temperature in a hood and placed
in individual ziplock bags containing a silica desiccant (Whatman,
Schleicher & Schuell, Keene, NH). DBS were stored at 220uC
until further processing and testing. The plasma was recovered
from the remaining blood sample by centrifugation and stored at
280uC for quantification of viral load using commercial (Roche)
RNA assays.
At the HEAL Africa Hospital (Goma, Democratic Republic of
Congo) site, DBS samples collected by heel stick from infants born
to HIV-1 positive mothers were stored and shipped to the
laboratory at ambient temperature; upon receipt in the laboratory,
the DBS samples were stored at 220uC until ready to be analyzed.
To better investigate whether the rtLC DBS assay could detect
and quantify across clades, in addition to the Congo DBS
specimens, we prepared dried spots of whole blood or plasma from
7 non-US origin patient samples (clades A, C, D, AE, AG) spiked
into HIV-1 negative donor blood.
Genotype Inclusivity Studies. Genotypic clade determina-
tion of patient viruses was done using RT-PCR followed by nested
amplification of were performed to amplify env and/or gag genes
from plasma HIV-1 RNA. Amplified products were cloned for bi-
directional DNA cycle sequencing using an ABI model automated
sequencer. Phylogenetic analyses based on env and gag nucleotide
sequences were used to determine the clade specificity.
DBS of International Panel of HIV-1 Isolates Representing
Globally PrevalentStrains. Referenceviruses (13CCR5-tropic
and 1 CXCR4-tropic) were obtained from the NIHAIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH
(Catalog #11412).[25] This panel represented 6 major globally
prevalent HIV-1 clades (A, B, C, D, and circulating recombinant
forms CRF01_AE and CRF02_AG).
RNA from these reference viral isolates was extracted using the
QIAamp Viral RNA mini kit, according to manufacturer’s
instructions (Qiagen, Valencia, CA), eluted in 60 ml of elution
buffer and then diluted 1:1000. A DBS panel was prepared by
mixing 60 ml of each virus isolate with 240 ml of seronegative donor
whole blood and then spotting 50 ml of this spiked donor blood onto
903 filter paper. Using the protocol described below, this dried
blood spot panel was extracted and run in the rtLC DBS assay.
Effect of Storage Time and Temperature on Stability of
DBS Samples. Plasma samples of 12 patients from 5 countries
with known viral loads were selected. Plasma (25 ul) was spiked
into 25 ul of HIV-1 negative donor whole blood to prepare DBS.
DBS at 220uC and 37uC storage temperatures were extracted on
day 1 and day 7 post-preparation. Due to limited quantity of
plasma, 8 out of 12 patient-DBS stored at these 2 temperatures
were extracted only on day 7 post-preparation.
Preparation of Standard Curve. To ensure uniformity and
reproducibility in the DBS preparation and extraction process, we
prepared customized DBS standards with known viral copies. An
HIV-1 clade B infected patient isolate with known viral load was
selected and spiked into HIV negative donor whole blood to
prepare DBS in five fold serial dilutions. A series of 5 independent
extractions were performed and quantified using the rtLC DBS
assay in a total of 25 independent runs.
RNA Extraction. Each DBS containing 50 ml of whole blood
was cut into 4 equal pieces and incubated for 5 minutes in Tris-
EDTA buffer (1.0 M Tris-HCl, 0.1 M EDTA) at room
temperature. HIV-1 RNA was extracted from the filter paper
using Trizol reagent as lysis solution according to the
manufacturer’s instructions (Invitrogen, Carlsbad, CA). Glycogen
(200 mg) was added to the lysis reagent as a carrier to facilitate
RNA precipitation for each DBS extraction. After removing the
residual filter paper, 1-bromo-2-chloropropane (BCP) was used to
separate the extracted RNA from the organic phase. RNA was
ethanol precipitated, eluted and further reconstituted in 40 mlo f
Rnase-free water containing 40 units of Rnasin Plus, an Rnase
inhibitor (Promega, Madison, WI).
DNA Extraction. One spot each of DBS filter paper was
processed to extract DNA using the previously described resin-
based Chelex (Bio-Rad, Hercules, CA) method.[26] Briefly, the
paper punched from one entire DBS was immersed in 1 mL of
whole blood specimen wash solution (Amplicor HIV-1 Monitor
HIV Diagnosis Using DBS
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room temperature. After a quick spin for 5 minutes at high speed,
the red-tinged buffer was removed and discarded. The DBS paper
was washed once, and then immersed in 250ul of Chelex resin
resuspended in DNA dilution buffer (10% v/v in 10 mM Tris
buffer, pH 8.3 containing 50 mM KCl). DNA kit Internal Control
(3.3ul) was added to the DBS sample, mixed frequently to keep the
resin in suspension, and was heated to 100uC for 1 hour, with a 10
second vortex after the first 30 minutes of heating. After a spin for
3 minutes to pellet the resin, the supernatant containing the extracted
DNA was removed and stored at 280uC until HIV-reactivity of the
extract was determined using Roche Amplicor HIV-1 DNA
Amplicor 1.5 v kit according to a previously published
protocol.[26] The cellular equivalents of DNA in each test sample
were determined in a real-time Taqman PCR assay by probing for
CCR5 copy number using forward primer 59-GCTGTGTT-
TGCGTCTCTCCCAGGA-39 and reverse primer 59-CTC-
ACAGCCCTGTGCCTCTTCTTC-39, and the corresponding
fluorogenic probe 59FAM-AGCAGCGGCAGGACCAGCCC-
CAAG-TAMRA 39. Known copies of plasmid carrying the CCR5
Table 1. Characteristics of the HIV-1 infected patients of US and Non-US origin studied.
Viral load (copies/ml)
Patient ID Country of origin/clade Age of patient (yrs) Patient on ART at visit bDNA Roche US rtLC DBS
P-1014 US 17 No 8068 11024 16144
P-1008 US 21 No 45484 142176 52920
P-1023 US 16 No 68654 170000 90680
P-1039 US 12 No 2076 7001 5424
P-1025 US 17 No ,75 271 ,37
P-1017 US 17 Yes 2910 7755 11208
P-1036 US 12 Yes 3144 6846 13120
P-1325 US 13 Yes 34332 92001 52760
P-1047 US 12 Yes N/A ,50 ,37
P-1020 US 18 Yes ,75 ,50 ,37
P-1031 US 14 Yes N/A 20952 9960
P-1012 US 20 Yes 485 1323 5624
P-1048 US 10 Yes N/A ,50 ,37
P-1115 US 15 Yes 9843 17613 3228
P-1033 US 15 No 19579 20082 42580
P-1040 US 13 Yes ,75 ,50 ,37
P-1336 US 19 No 29908 39466 21468
P-1341 US 17 Yes 226 ,50 ,37
P-1046 US 12 Yes 739 589 4606
P-1319 US 8 Yes 11531 9853 8792
P-1117 US 12 Yes N/A 8380 7129
P-1363 US 14 Yes N/A 19900 6000
P-1107 US 19 NO 4940 11832 1771
P-1366 US 9 No N/A 43617 36242
P-1044 US 13 Yes 2421 3396 15848
P-1339 US 7 Yes 298 ,50 ,37
A1 US/B 40 No N/A 160070 214400
A2 US/B 52 No N/A 898462 2379600
A3 US/B 48 No N/A 136048 57140
A4 US/B 47 No N/A 484018 786600
P-1347 Burundi/A 15 No N/A 13605 26250
P-1211 Cambodia/AE 9 Yes ,75 ,50 ,37
MDOT 25 Cambodia/AE 8 N/A N/A 220456 29480
MDOT 22 Cambodia/AE 1 N/A N/A 271744 159120
P-1210 Liberia/AG 10 Yes N/A 135417 166360
P-1359 Liberia/AG 13 No 12509 207236 122600
P-1334 Zambia/C 14 No N/A 196285 26440
N/A=Not Available
ND=Not Detected
doi:10.1371/journal.pone.0005819.t001
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number of CCR5 copies and cellular equivalentswere determined for
each sample. Real-time PCR analyses on RNA extracted from infant
DBS was performed as described below.
Real-time PCR. Real-time PCR amplification of HIV-1 RNA
was performed in a one-step, single-tube closed system of 32 sample
format using the LC-32 Roche LightCycler (Roche, Indianapolis,
IN). All the samples were tested in duplicate in a 20 ml total reaction
volume containing 16 ml of PCR reaction mix (Quantitect SYBR
Green RT-PCRkit [Qiagen, Valencia, CA]; 0.5 mMe a c ho ffo r w a rd
and reverse oligonucleotide primer pairs) and 4 ml of the template.
The primers were specific to a conserved region of HIV-1 LTR: 59-
GRAACCCACTGCTTAASSCTCAA-39 (LTR sense; position 506
of HxB2) and 59-TGTTCGGGCGCCACTGCTAGAGA-39 (LTR
antisense; position 626 of HxB2).[27] The PCR reaction was
performed according to the following cycling parameters: 1)
Reverse-Transcription: 50uC2 0m i n u t e s ,r a m p2 0 uC/second; 2)
Activation: 95uC1 5m i n u t e s ,r a m p2 0 uC/second; 3) Amplification:
50 cycles a) 94uC1 0s e c o n d s ,r a m p2 0 uC/second, b) 52uC2 0
seconds, ramp 20uC/second, and c) 72uC 20 second, ramp 2uC/
second (single data collection); 4) Melting: a) 92uC0s e c o n d ,r a m p
20uC/second,b)57uC1 5se c o n d s ,ra mp2 0 uC/second,andc)92uC0
second, ramp 0.1uC/second (continuous data collection); 5) Cooling:
40uC3 0s e c o n d s ,r a m p2 0 uC/second.
HIV-1 specific amplicons were detected using SYBR Green
technology according to manufacturer’s instructions (Qiagen,
Valencia, CA). The number of HIV-1 RNA copies in each test
template was measured by its threshold cycle (Ct) and determined
from the standard curve of serially diluted customized DBS
standards using software for data analysis (Sequence Detector
version 1.6, PE Applied Biosystems). For each experiment, a
standard curve was generated from serial endpoint dilutions
(586,000 to 37 copies) of the customized DBS standards. The
threshold cycle values were plotted against copy numbers to
construct the standard curve. QuantificationofHIV-1RNAineach
test sample was back calculated and viral load was expressed as
copies/ml. Using the protocol described above, DBS was extracted,
run and analyzed in the rtLC DBS assay by personnel with
molecular and virology expertise who were blind to the results.
Rnase-free water (4 ml) was routinely added instead of test sample
to 16 ml of the master mix and used as a no-template control for
every run. At the end of the assay, the specificity of each amplified
product was ascertained by means of melting curve analysis. This
eliminated false positive detections due to primer dimers or non-
specific amplicons. To confirm that there was no DNA contami-
nation in the input RNA and to assess the specificity of the reverse
transcribed rtLC DBS products, initial assays included PCR
reactions without the addition of reverse-transcriptase enzyme.
Gel electrophoresis of the amplicons was initially performed to
further confirm the specificity of the products. Each sample was
tested in replicates and a second DBS was independently extracted
and run to verify a positive result. The test was repeated if the
sample had indeterminate results, and if necessary a new spot was
extracted and tested if the results of the repeat test were also
indeterminate. Quality control for each experiment was assessed by
the performances ofthe standard curve and the negative control. All
DBSpreparedbytrainedpersonnelwere tested forthisstudyaslong
as multiple filter spots were available for each patient, and the blood
spots were good quality with no hemolysis or clots.
To determine whether viral load data using the Roche LightCycler
system were comparable to viral load data obtained by using
MyiQ
TM Single-Color Real-Time I-Cycler PCR Detection System,
(Bio-Rad, Hercules, CA), cDNA synthesis was carried out with the
i S c r i p tc D N AS y n t h e s i sK i t( B i o - R a d ,H e r c u l e s ,C A ) .S e l e c tp a t i e n t
and standard DBS-RNA were used to synthesize cDNA, and then
amplified and quantified using the iQ SYBR Green Supermix Kit
(Bio-Rad, Hercules,CA) by using theseparameters:3 min @95C,50
cycles of 10 sec @94C, 20 sec @52C, 20 sec @72C, and final
extension for 20 sec @72C. Results were analyzed using MyiQ
software, version 1.0.410 (Bio-Rad, Hercules, CA).
Sensitivity and Linearity of the Assay. Linearity of the
assay was evaluated using serial dilutions of the customized
standard DBS described earlier (586,000 copies to 37 copies).
Statistical Analyses. The customized DBS standards serial
dilutions were tested in 25 separate runs to determine the
threshold, inter-assay precision and linearity of the rtLC DBS
assay. Trained statisticians performed data analyses. Probit
analysis was used to determine 95% and 99% detection limits.
The likelihood ratio test was used to evaluate the effect of
extractions and runs; the fitness was measured by R-squared value.
Spearman correlation coefficients were calculated to determine the
relationship between the HIV-1 RNA levels quantified by the
Roche Ultrasensitive and bDNA assays with the rtLC DBS
technique. The sensitivity of the rtLC DBS assay was calculated as
the number of positive results divided by the total number of
samples from infected patients who had plasma viral load above
the threshold level of detection of commercial assays (bDNA and
Roche Ultrasensitive) expressed as a percentage. The specificity
was calculated as the number of negative samples divided by the
total number of known negative specimens obtained from normal
healthy donors and uninfected infants expressed as a percentage.
Paired Wilcoxon tests were used to determine the effect of
temperature and time on RNA stability and assay performance.
Results
Linear Range, Detection Limits and Inter-assay Precision
of the rtLC DBS Assay
The linear dynamic range of the rtLC DBS assay was initially
assessed using a 5 log10 dilution series of the customized standard
DBS. The assay was shown to be linear over the entire range of
586,000 to 37 copies. A linear regression of the rtLC DBS
customized standards copies on true concentrations yielded a
correlation coefficient of 0.984 (P,0.001) and the fitted model is
shown in Figure 1. The slope of 1.037 closely approximates the
theoretical maximum amplification efficiency of 100%; the fitted
slope is slightly greater than 1 due to the several undetected cases
in low range. To estimate the detection limit of the assay, we
performed 22 extra runs at low concentrations (7, 17, 37, 83, 187
copies), which spread evenly in log scale and contained two
concentration 37 and 187 that were already in design. We used all
available data at concentrations from 7 to 937 to fit the probit
model to get estimations for 95% detection limit as 135, with 95%
confidence interval [82, 223]; 99% detection limit was estimated
as 292, with 95% confidence interval [147, 583] (Table 2).
To evaluate the inter-assay precision of the assay, the data on
the customized DBS standards of known concentrations (586,000
to 37 copies) were analyzed across 25 independent experiments.
The results of the statistical analysis for the standard deviation (SD)
and percent coefficient of variation (%CV) at each concentration
level are shown in Table 3. The coefficient of variation increased
dramatically when the true concentration was approximately
equal to or below the assay’s detection limit.
Sensitivity and Specificity of the rtLC DBS Assay
The clinical sensitivity of the assay was determined using DBS
specimens of 32 patients with known infection and viral loads
above the detection threshold of the bDNA and Roche
HIV Diagnosis Using DBS
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the rtLC DBS assay, yielding a clinical sensitivity of 100% for this
cohort. An additional 5 DBS samples drawn from infants of
indeterminate HIV-1 infection status tested positive on the rtLC
DBS assay; all 5 were also positive on the commercial DNA assay.
The clinical specificity of the rtLC DBS assay was determined
using DBS specimens from 27 healthy HIV-1 negative adult
donors and 17 HIV-1 negative infants born to HIV-1 positive
women. All of these samples were negative for HIV-1 RNA,
resulting in a clinical specificity of 100%. The information on the
clinical specificity of rtLC DBS assay in HIV negative donors is
provided in Table S1 in the supplementary section.
rtLC Assays Using Samples Collected in the Field
DBS samples from infants born to HIV positive women were
also prepared at a clinical site in Goma, Congo. The range of cell
equivalents across these Congo DBS samples was 2,769 to 201,116
Figure 1. Linearity of the rtLC DBS assay using dilutions of known concentrations of HIV-1 from a clade B infected patient. The
concentrations quantified by rtLC DBS assay obtained from 25 experiments were plotted against true standard plasmid concentrations. They ranged
from 37 copies to 586,000 copies/reaction sample with a correlation of 0.984 (P,0.001).
doi:10.1371/journal.pone.0005819.g001
Table 2. Calculation of the 95% and 99% detection limit of
the rtLC DBS assay using probit analysis.
Actual concentration
(copies/reaction)
Measured
concentration (median
copies/reaction)
Number of positive
reactions/total test
reactions (%)
Four concentrations
.=4688
-- 100/100(100%)
292 248 99%*
937 941 25/25 (100%)
187 188 44/46 (95.7%)
136 112 95%*
83 56 17/22 (77.3%)
37 39 38/47 (80.9%)
17 9 11/22 (50%)
7 0 2/22 (9%)
*The assay sensitivity was calculated using 22 replicate measurements for low
range concentrations between 7 and 187 copies. Results from concentration
37, 187 and 937 copies from 25 runs of standard curve data were also used for
Probit fitting. The data used for the analyses are shown in regular typeface and
the estimated 99% and 95% detection limits are shown in boldface.
doi:10.1371/journal.pone.0005819.t002
Table 3. Precision of the rtLC DBS assay: The standard
deviation and the percent coefficient of variation were
calculated using data from 25 independent experiments.
Actual
concentration
(log copies/
reaction)
Measured
concentration
(average, log
copies/reaction)
Standard
deviation
(SD)
% Coefficient
of variation
(% CV)
5.77 5.79 0.14 2.5
5.07 5.15 0.15 3.0
4.37 4.28 0.18 4.2
3.67 3.69 0.15 4.0
2.97 2.85 0.49 17.1
2.27 2.20 0.22 10.1
1.57 1.43 0.55 38.7
doi:10.1371/journal.pone.0005819.t003
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determined in the DNA extracts as shown in Table 4. An aliquot
of RNA for each sample was spiked into normal human plasma
and run on a Roche Amplicor HIV-1 Monitor Ultrasensitive
assay. DNA testing determined that 5 of 19 samples were positive
for proviral DNA. These same 5 samples were positive using the
rtLC DBS assay (range=11,084 to 1,123,400; median 196,200
copies/ml) with RNA copy numbers similar to the values obtained
on the Roche Amplicor assay.
Genotype Inclusivity
The rtLC DBS assay successfully detected HIV-1 RNA in each
of the DBS samples prepared from 14 viral isolates representing an
international HIV-1 reference panel (clades A, B, C, D and CRF-
AE and CRF-AG).
The rtLC DBS assay also successfully detected and quantified
HIV-1 RNA in DBS samples prepared in our lab using whole
blood samples from 23 patients (US origin) infected with clade B
virus (Table 1), and 6 patients (non-US origin) infected with non-
clade B virus (Table 1). Finally, the rtLC DBS assay successfully
detected HIV-1 nucleic acids in the blood of all 5 HIV-1 positive
Congo infant DBS samples that were prepared in the field and
shipped at ambient temperature (Table 4).
Comparison of Viral Load Measurements Using the rtLC
DBS Assay and Commercial Viral Load Assays
Plasma viral RNA copy numbers determined by the rtLC DBS
assay were compared to results obtained using commercial assays
(bDNA and Amplicor). The Spearman coefficients of rtLC DBS
with the Roche and bDNA assays were 0.91 and 0.89 respectively.
In a pilot study using the i-Cylcer real-time PCR system to
quantify viral load from select patient and standard DBS RNA
preparations, and using Sybr Green dye for detection, we
demonstrated comparable performance to that of the LightCycler
system (Figure S1; Supplementary section). A significant correla-
tion between i-Cycler and LightCycler based viral loads was
observed in DBS specimens (Spearman Ranks correlation,
p,0.0001) suggesting that our LightCycler-based DBS assay will
have universal applicability.
Effect of Ambient Temperature on Stability of HIV-1 RNA
To evaluate the performance of this assay in limited resource
settings where storage and shipment of DBS at ambient/room-
temperature (.25uC) is the norm, we investigated the effect of
37uC temperature on the stability of DBS/RNA, by comparing
the detection of HIV-1 RNA in DBS samples stored at 220uCo r
37uC. We also evaluated 7 days of storage at 37uC to emulate
shipment of DBS from the point of preparation (clinic) to a tertiary
referral center (reference-laboratory), and compared the assay
results to those of identical DBS stored promptly at 220uC. No
statistically significant difference in viral load was observed for 12
samples stored either at -20uCo r3 7 uC (Wilcoxon signed rank test,
p=0.06) (Figure 2). Further, to evaluate for potential loss of RNA
over time in DBS samples stored at 220uC and 37uC, viral load
was determined on RNA samples extracted day 1 and day 7 post-
preparation of DBS. The data (available for 8 patients) for days 1
and 7 were comparable irrespective of the storage temperature
(paired Wilcoxon test; data not shown).
Extraction and Inter-assay Efficiency
The fitness measured by R-squared value in the simplest model,
which includes only the true concentration as predictor, is 0.955,
and R-squared values from models that include extraction and run
effects were 0.9959 (extraction and run) and 0.9948 (extraction),
respectively. The improvement of fitness by including extra
extraction specific parameters and run specific parameters are
marginal, and we conclude that true concentration explains most
(95.5% percent) of the variation in observed concentration, and
the influence of extractions and runs are limited.
Figure 2. Comparison of viral load from DBS of 12 patients,
stored at 220uC and 37uC, extracted on day 7 post-preparation
and quantified by rtLC DBS assay.
doi:10.1371/journal.pone.0005819.g002
Table 4. Results of the infant DBS samples prepared onsite at
HEAL Africa Hospital in Goma, Democratic Republic of Congo.
Viral load (copies/ml)
Congo ID Cells/DBS HIV-1 provirus Roche US rtLC DBS
CO323D 20711 Neg NT Neg
CO473D 63879 Neg NT Neg
CO472D 44936 Neg Neg Neg
CO259D 87188 Neg NT Neg
CO319 196893 Neg NT Neg
CO403 152982 Neg neg Neg
CO404 126770 Pos 2240 11084
CO413 114980 Pos 436160 196200
CO460D 86618 Neg neg Neg
CO487D 201116 Pos 82560 179520
CO534 161767 Neg NT Neg
CO219D 2769 Neg NT Neg
CO461D 178125 Pos 1467520 1,123,400
CO533D 94875 Neg Neg Neg
CO513D 17741 Neg NT Neg
CO530D 13388 Neg NT Neg
CO599D 95625 Pos 617600 206,460
CO644D 39048 Neg NT Neg
CO647D 32887 Neg NT Neg
Pos, positive; Neg, negative; NT, not tested
doi:10.1371/journal.pone.0005819.t004
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on ART
The rtLC DBS assay was used to monitor plasma HIV-1 RNA
levels in two patients for up to one year on ART (Figures 3a and
3b). The rtLC DBS assay showed good correlation with the Roche
Ultrasensitive assay for the longitudinal follow-up of these two
patients, suggesting that it may also be useful for monitoring viral
load in patients on ART.
Discussion
In this study, we used a nucleic acid based real-time PCR assay
to detect and quantify plasma HIV-1 copy numbers on samples
from 56 HIV-1 infected patients utilizing the DBS format. The
assay results were comparable and correlated well with commer-
cially available viral load assays (Siemens bDNA, Spearman
r=0.89 and Roche Ultrasensitive Amplicor, Spearman r=0.91).
In the patient cohort analyzed, the assay successfully detected all
positive samples. The calculated specificity using known negative
samples was 100%. The estimated 95% detection threshold was
136 copies and the dynamic range of the assay was 5 log10. Finally,
the assay successfully detected four major subtypes and 2 CRF of
HIV-1.
A little over a decade ago, we demonstrated the utility of early
combination antiretroviral therapy (ARV) in infants.[28,29] HIV
infection is associated with particularly high morbidity and
mortality in limited-resource settings and a recent randomized
trial conducted in South Africa demonstrated reduced morbidity
and mortality in infants treated with early combination ARV.[30]
In a recent WHO consultants’ meeting, revision of current
guidelines was recommended to include routine early diagnosis
and treatment of HIV positive infants under 1 year of age.[31]
Nucleic acid based testing is the gold standard for early diagnosis.
Commercially available assays (bDNA, Roche Amplicor Ultra-
sensitive, and Cobas) are relatively expensive and require
significant infrastructure and technical expertise to allow transfer
of technology to resource-limited settings.[2,8] Hence access to
nucleic acid testing in these settings is currently very limit-
ed.[6,17,18,32,33]
Studies to detect and quantify HIV-1 have traditionally involved
two-step, nested or probe based PCR [34–37]; more recently, real
time PCR has been used for HIV detection and quantifica-
tion.[6,22,24,34,38,39] Multiple investigators have documented
the utility of DBS sample collection for early HIV-1 detection in
infants, viral load monitoring, and surveillance of seropositivity
and drug resistance in laboratories and clinics that lack facilities for
refrigeration or sample processing.[8,17,20,22–24,38,40–52] The
DBS format greatly facilitates the logistics of sample collection,
processing, and shipping for limited resource settings. Whole blood
saved as DBS can be transported or mailed to reference
laboratories without refrigeration and has low biohazard risk.
Optimal storage conditions for DBS and long term stability of
DNA and RNA from DBS under different storage conditions have
been extensively documented.[23,44,47,51,53] Our pilot studies
with a small cohort of patient samples to assess the effect of
temperature and time, albeit one week, on the stability of RNA
demonstrated no difference, and were in agreement with previous
larger studies.[39,54–56] Comparable efficacy using multiple
extractions and runs of our customized standards support the
reliability of the DBS format and the rtLC DBS assay.
The rtLC DBS assay described herein is a one-step, walk away
technique. Automation of this assay provides potential for high
throughput with very small sample volumes, which makes the
assay suitable for use in infants and children from whom one often
has access to only small blood volumes. It is an assay system which
will be cost-effective and easily adaptable to limited-resource
settings, where the majority of new HIV-1 infections are seen
today. The detection of PCR products by SYBR Green ensures
good sensitivity. SYBR Green is relatively inexpensive compared
to probe-based detection, and in general, SYBR Green detection is
one cycle threshold or so more sensitive than probe-based assays.
Several previous studies have utilized SYBR Green for HIV-1
diagnosis and are reviewed by Espy et al.[57] The efficiency of this
dye-based assay is also comparable with the currently available
diagnostic assays on HIV. Aside from use in HIV diagnosis and
quantification, SYBR Green has been widely used to detect and
quantify diverse human pathogens.[58–65] The data in these
reports strongly support the utility and reliability of SYBR Green
for detection of specific PCR amplicons above the background.
The use of degenerate LTR primers in the rtLC DBS assay allows
for a wide range of genotype inclusivity.
Compared to commercial assays, the rtLC DBS assay is rapid
and cost-effective. The equipment used in the rtLC assay is self-
Figure 3. a & b. Comparison of viral load measurements
quantified by rtLC DBS and Roche Ultrasensitive assays for
patients on therapy followed longitudinally. (Fig 3a – Patient
1117; Fig 3b – Patient 1366).
doi:10.1371/journal.pone.0005819.g003
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accessory equipments (such as a plate washer, optical density
reader, and incubator; Table 5). Aside from the initial cost of
obtaining the LightCycler instrument, a comparative analysis of
assay costs and technician time reveals a 40-fold decrease in cost as
well as 2.5 fold decrease in technician time (4.5 hours) associated
with the rtLC DBS when compared to commercial kit based PCR
assays (Table 6).
The reduced equipment requirements, personnel hours, and
costs compared to the commercial ‘gold’ standard assays make the
rtLC DBS assay attractive for transfer to and use in resource-
limited settings. The success of the pilot field study on DBS from
Congo emphasizes the utility and applicability of our assay
although further studies with larger sample sizes are definitely
warranted.
In summary, we have utilized a real-time LightCycler based
PCR assay on small volumes of whole blood dried on filter paper
to successfully detect and quantify viral loads across different HIV-
1 clades. The use of dried blood spots provides a simple and
inexpensive means for obtaining blood samples for analysis that
minimizes the risk for contamination while maximizing the ability
to obtain timely results. A major advantage of the rtLC DBS assay
is that the amplification, real-time detection and quantification,
and confirmation of amplicon-specificity by melting curve analysis
are performed in a one-step, closed-tube format. In addition, viral
load tests by rtLC DBS assay are substantially less expensive and
logistically less intensive than commercial assays. Preliminary data
suggest the adaptability of the assay into other real-time systems.
Validation of these results with larger field studies would constitute
a more robust evaluation and will have major implications for
early diagnosis, disease management, and epidemiological- or
resistance- surveillance studies in limited resource settings.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0005819.s001 (0.04 MB
DOC)
Figure S1 Spearman Ranks correlation between i2Cycler (iC)
and LightCycler (LC) based real2time PCR systems to quantify
HIV 1 viral loads in 21 patients and 8 standard DBS (p,0.0001).
Found at: doi:10.1371/journal.pone.0005819.s002 (0.04 MB TIF)
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